Product Information
DEXTROAMPH-AMPHET ER 50 MG CAP is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $7.7857 per EA under NDC 00480368601. Its NADAC has been published 123 times since Apr 17, 2024.
FDA first approved this application on Jan 31, 2022. Its Orange Book therapeutic-equivalence code is AB2 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
DEXTROAMPH-AMPHET ER 50 MG CAP
dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfateStrength
12.5; 12.5; 12.5; 12.5 mg/1; mg/1; mg/1; mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00480368601
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
AMPHETAMINE ASPARTATE MONOHYDRATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATEApproval Type
Generic (ANDA)
FDA Application
ANDA210876FDA Approved
1/31/2022
TE Code
AB2
On Market Since
10/10/2023
Pharmacological Classes
Price Statistics
The NADAC for DEXTROAMPH-AMPHET ER 50 MG CAP has been published 123 times since Apr 17, 2024, and over the history we have for it it has declined 2.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $7.7857 per EA |
|---|---|
| All-time high | $9.1313 (May 14, 2025) |
| All-time low | $7.7184 (Jul 17, 2024) |
| 52-week high | $8.5829 |
| 52-week low | $7.7857 |
| Median price | $8.4735 |
| Average price | $8.4164 |
| Largest weekly change | -10.8% (Jul 17, 2024) |
| Weeks tracked | 123 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of DEXTROAMPH-AMPHET ER 50 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for DEXTROAMPH-AMPHET ER 50 MG CAP, manufactured by Teva Pharmaceuticals USA Inc., is $7.7857 per EA (NDC 00480368601), effective Aug 19, 2026.
How has the price of DEXTROAMPH-AMPHET ER 50 MG CAP changed over time?
Over the history we have for it, the NADAC for DEXTROAMPH-AMPHET ER 50 MG CAP has declined 2.0%. It has been tracked across 123 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for DEXTROAMPH-AMPHET ER 50 MG CAP?
Since Apr 17, 2024, the NADAC for DEXTROAMPH-AMPHET ER 50 MG CAP has ranged from a low of $7.7184 (Jul 17, 2024) to a high of $9.1313 (May 14, 2025), with a median of $8.4735 per EA.
Are there cheaper alternatives to DEXTROAMPH-AMPHET ER 50 MG CAP?
No other NADAC-published product currently shares the active ingredient and strength of DEXTROAMPH-AMPHET ER 50 MG CAP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DEXTROAMPH-AMPHET ER 50 MG CAP?
DEXTROAMPH-AMPHET ER 50 MG CAP (NDC 00480368601) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.